Skip to content

Author

S. H. Park

We have 2 of 51 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti-PD-(L)1 therapy.

BACKGROUND The phase 3, randomized, open-label LITESPARK-011 trial (NCT04586231) investigated belzutifan plus lenvatinib versus cabozantinib in participants with advanced clear-cell renal-cell carcinoma (ccRCC) following anti-PD-(L)1 therapy. At earlier analyses, belzutifan plus lenvatinib significantly improved progre...

D. Heng, M. Schmidinger, R. McDermott et al. · 0 citations
Open access Sep 2026

34 Belzutifan Plus Lenvatinib Versus Cabozantinib in Post–PD-(L)1 Renal Cell Carcinoma: Health-Related Quality-of-Life Outcomes in the Phase 3 LITESPARK-011 Study

Results support belzutifan plus lenvatinib as a new treatment option for advanced RCC that progressed after anti–PD-(L)1 therapy and support belzutifan plus lenvatinib as a new treatment option for advanced RCC that progressed after anti-PD-(L)1 therapy.

M. Schmidinger, D. Heng, Ray McDermott et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.